Related Experiment Videos
Role of genetic prothrombotic risk factors in childhood caval vein thrombosis
N Münchow1, A Kosch, R Schobess
1Paediatric Haematology and Oncology, University Hospital Hamburg-Eppendorf, Hamburg, Germany. muenchow@uke.uni-hamburg.de
Insights
Genetic prothrombotic risk factors are significant in childhood caval vein thrombosis. The factor V G1691A mutation is more common in infants, while the prothrombin G20210A variant is prevalent in adolescents.
Area of Science:
- Pediatric Thrombosis
- Vascular Medicine
- Genetics
Background:
- Childhood caval vein thrombosis (CVT) is a serious condition, particularly in infants.
- Several genetic and acquired prothrombotic risk factors are implicated in pediatric vascular accidents.
Purpose of the Study:
- To investigate the prevalence of specific prothrombotic risk factors in children with inferior caval vein thrombosis.
- To determine the association of these factors with the age of thrombotic onset.
Main Methods:
- A case-control study involving 27 pediatric patients with inferior CVT and 100 healthy controls.
- Analysis for factor V (FV) G1691A mutation, prothrombin (PT) G20210A variant, methylenetetrahydrofolate reductase (MTHFR) TT677 genotype, and lipoprotein (Lp) (a) levels.
- Assessment of antithrombin deficiency and hyperhomocysteinemia.
Main Results:
- 68.4% of infants with CVT had at least one prothrombotic risk factor.
- The FV G1691A mutation was more frequent in infants (n=5), while the PT G20210A variant was predominant in adolescents (n=3).
- Overall, prothrombotic risk factors showed a significant odds ratio of 9.2 for CVT in infancy.
Conclusions:
- Genetic prothrombotic risk factors are crucial in pediatric CVT.
- The FV G1691A mutation is a key risk factor in infancy.
- The PT G20210A variant is a significant risk factor during puberty and adolescence.
Unlabelled:
Childhood caval vein thrombosis has a high incidence especially in the first year of life. Besides deficiencies of protein C, protein S, antithrombin and plasminogen, the factor (F) V G1691A mutation, the prothrombin (PT) G20210A variant, the methylenetetrahydro-folate reductase (MTHFR) TT677 genotype, or increased lipoprotein (Lp) (a) > 30 mg/dl have emerged as important prothrombotic risk factors in childhood vascular accidents. 27 consecutive childhood patients with inferior caval vein thrombosis and 100 healthy age-matched controls were investigated for the presence of these prothrombotic risk factors with respect to the first thrombotic onset. In 19 out of 27, patients thrombosis occurred during infancy; the remaining vascular accidents were diagnosed during puberty. In 13 out of the 19 infants, vascular occlusion occurred spontaneously, five times associated with renal venous thrombosis. 68.4% of patients in the first year of life (n = 13) showed at least one prothrombotic risk factor. The FV mutation (heterozygous n = 4, homozygous n = 1). Lp (a) > 30 mg/dl and kringle 4 repeats < 28 (n = 4), MTH FR TT677 with mild hyperhomocysteinaemia (> 95th age-dependent percentile, i.e. 8.5 micromol/l: n = 3) and antithrombin deficiency type II (n = 1) were diagnosed with an overall odds ratio/95% confidence interval of 9.2/3.1-27.4. In the adolescent group, genetic risk factors were found in 50% of patients investigated (FV mutation (n = 1), PT variant (n = 3); odds ratio/95% confidence interval: 4.2/0.97-18.6).
Conclusion:
Data presented here suggest that genetic prothrombotic risk factors play an important role in childhood caval vein thrombosis. Remarkably, during puberty and adolescence the predominant defect diagnosed was the PT G20210A variant, whereas the FV G1691A mutation had a higher incidence during infancy.
Related Concept Videos
Venous Thrombosis I: Introduction
Varicose Veins I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins